GeoVax Labs Q3 2024 Earnings Report $2.29 -0.03 (-1.29%) (As of 12/20/2024 05:40 PM ET) Earnings HistoryForecast GeoVax Labs EPS ResultsActual EPS-$0.91Consensus EPS -$1.29Beat/MissBeat by +$0.38One Year Ago EPS-$4.80GeoVax Labs Revenue ResultsActual Revenue$2.79 millionExpected Revenue$1.84 millionBeat/MissBeat by +$950.00 thousandYoY Revenue GrowthN/AGeoVax Labs Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptGOVX Earnings History Wall Street Icon: “You must get on the right side of this thing” (Ad)I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.This market shakeup is going to be much more intense. GeoVax Labs Earnings HeadlinesGeoVax Labs (NASDAQ:GOVX) to Reconvene Special Stockholders MeetingDecember 20 at 4:13 AM | americanbankingnews.comNoble Financial Remains a Buy on GeoVax Labs (GOVX)December 11, 2024 | markets.businessinsider.comWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.December 22, 2024 | InvestorPlace (Ad)GeoVax Receives Notice of Allowance For Cancer Vaccine PatentDecember 9, 2024 | globenewswire.comGeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity ConferenceNovember 26, 2024 | globenewswire.comGeoVax Labs’ Promising Vaccine Trials Enhance Buy Rating Amid Robust Immune Response and Market PotentialNovember 21, 2024 | markets.businessinsider.comSee More GeoVax Labs Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GeoVax Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GeoVax Labs and other key companies, straight to your email. Email Address About GeoVax LabsGeoVax Labs (NASDAQ:GOVX), a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.View GeoVax Labs ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
